Melioidosis–Tuberculosis Cytokine Profiling Study

Le résumé fourni par la source

This study investigated systemic cytokine responses in adults with acute melioidosis and pulmonary tuberculosis (PTB) in an endemic region of southern India (2021–2024). A total of 64 participants were enrolled and stratified into six groups: melioidosis with diabetes mellitus (DM) (n=8), melioidosis without DM (n=8), PTB with DM (n=8), PTB without DM (n=8), DM controls without acute infection (n=16), and non-diabetic healthy controls (n=16). Melioidosis was confirmed by culture isolation of Burkholderia pseudomallei from clinical specimens. PTB was diagnosed by sputum smear positivity (≥3+) and detection of Mycobacterium tuberculosis using Xpert MTB/RIF. Diabetes status was defined according to WHO criteria. Plasma samples were collected at hospital admission for assessment of immune responses. Figure 1: Clinical profile comparison between melioidosis and PTB patients. Data are presented as the percentage of patients exhibiting specific symptoms. Statistical comparisons were performed using chi-square analysis. Figure 2: Plasma cytokine profiles across melioidosis (n=16), PTB (n=16), and control groups (n=32). Cytokines were measured using a Human Cytokine Magnetic 10-plex multiplex Luminex assay (MAGPIX platform). Concentrations are expressed in pg/mL. Figure 2A shows a heatmap of log10-transformed median cytokine concentrations across groups. Figures 2B–E present plasma levels of Galectin-3 (Gal-3), hepatocyte growth factor (HGF), IL-6, and IL-8. Data are displayed as median with interquartile range (IQR). Statistical comparisons were performed using the Kruskal–Wallis test with Dunn’s post hoc correction. Figure 3: Receiver operating characteristic (ROC) curve analysis evaluating the discriminatory performance of Gal-3, HGF, IL-6, and IL-8. Area under the curve (AUC) values are shown for melioidosis versus controls, PTB versus controls, and melioidosis versus PTB. Figure 4: Principal component analysis (PCA) of clinical and cytokine variables across melioidosis, PTB, and control groups. ROC analysis of predictive models is also shown, including Model 1 (cytokines only), Model 2 (clinical parameters only), and Model 3 (combined cytokine and clinical parameters), with corresponding AUC values.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.